General contact

Main switchboard
Switzerland

+41 61 324 11 11
+41 61 324 80 01
Monday - Friday,
8:30 a.m. - 5:00 p.m. GMT+1

US switchboard

+1 862 778 21 00
Monday - Friday,
8:30 a.m. - 5:00 p.m. EST

Media

Global Media Relations
Eric Althoff
Basel, Switzerland

+41 61 324 7999

Investors

Investor Relations
Switzerland

Monday - Friday,
8:30 a.m. - 5:30 p.m. GMT+1
(Central European Time)

Reporting side effects

Report a suspected side effect (also known as an adverse event) related to a Novartis Pharmaceutical drug or a Novartis Vaccine.

Reporting side effects

pane 4 content

Alcon information center

  • Certain information on the merger
    Merger effective date
     
    April 8, 2011
    (23:59 (New York time))
    Novartis share ISIN CH0012005267
    Novartis ADS CUSIP 66987V109
    Tax reporting 1099-B
    Cost basis reporting type Fully taxable
    Share lot holding period treatment Fair market value
    Fair market value per Novartis share CHF 50.75
    Fair market value per Novartis ADR USD 55.30
    Fair market value date Merger effective date
    Contingent Value Amount per Alcon share (gross)
     
    CHF 7.5150
    USD 8.1993
    Swiss Withholding Tax on Contingent Value Amount
     
    CHF 2.6303
    USD 2.8698
    Contingent Value Amount per Alcon Share (Net)
     
    CHF 4.8847
    USD 5.3295
    Swiss Withholding Tax on nominal value amount increase CHF 0.6792
    Grossed-up nominal value amount increase CHF 1.9406
    USD/CHF exchange rate 0.91654405
  • Information related to the Extraordinary General Meeting

    The Novartis Extraordinary General Meeting took place in Basel, Switzerland on April 8, 2011

    Notice of Extraordinary General Meeting

    Brochure “Important Shareholder Information”

    For holders of American Depositary Receipts (ADRs)

    Contact information for merger exchange:

    BNY Mellon Shareowner Services
    International Phone +1-201-680-6579
    Domestic Phone (U.S.) +1-866-401-0295

    Globetax
    International Phone +1-212-747-9100
    Domestic Phone (U.S.) +1-800-845-2416

  • Materials for inspection

    Materials for inspection related to the merger of Alcon, Inc. with and into Novartis AG pursuant to article 16 of the Swiss Merger Act.

    Brochure “Important Shareholder Information”

    The brochure encloses:

    • Merger Agreement dated December 14, 2010, entered into by Novartis AG and Alcon, Inc. including the merger balance sheets.
    • Joint Merger Report report prepared in connection with the merger between Novartis AG and Alcon, Inc. by the board of directors of both entities.
    • Audit Report prepared in connection with the merger between Novartis AG and Alcon, Inc.


    Annual Report 2010 cover

    Annual Report 2010

    Annual Report 2009 cover

    Annual Report 2009

    Annual Report 2008 cover

    Annual Report 2008


    The annual financial statements and the annual reports of the last three business years of Alcon, Inc. are available from the Investors and Media section of Alcon's website at http://www.alcon.com.

  • Other Alcon-related information

    February 25, 2011

    The US Securities and Exchange Commission declared effective the company's registration statement on Form F-4 relating to the merger. Effectiveness of Form F-4 marks a milestone for the closing of the merger, with a last condition receipt of two-thirds approval by the shareholders of both Novartis and Alcon voting at their respective meetings.

    December 15, 2010

    Novartis announced it has entered into a definitive agreement with Alcon, Inc. (Alcon; NYSE: ACL) to merge Alcon into Novartis for Novartis shares and a Contingent Value Amount (CVA).

  • Novartis VWAP calculation for Alcon merger
    Day Date Novartis share 1-day VWAP (CHF) Volume USD/CHF exchange rate (at 4:30 pm London time) Novartis share 1-day VWAP (USD)
    1 March 24 49.3711 12,713,484 0.9067 54.4514
    2 March 25 50.7954 10,638,749 0.9182 55.3206
    3 March 28 50.8478 7,644,039 0.9174 55.4260
    4 March 29 50.2621 7,502,433 0.9209 54.5793
    5 March 30 50.2343 7,419,763 0.9225 54.4545
    6 March 31 49.9137 10,253,559 0.9161 54.4850
    7 April 1 49.8603 9,619,468 0.9279 53.7346
    8 April 4 50.0069 8,083,585 0.9228 54.1904
    9 April 5 50.8554 9,819,465 0.9247 54.9966
    10 April 6 50.7545 6,585,874 0.9175 55.3183
       Novartis Share Value1,2 54.6738
       Exchange Ratio1 2.9228
       Contingent Value Amount1,3 8.20

    1Indicates a term defined in the Merger Agreement
    2Shown rounded to four decimal places
    3Shown rounded to nearest cent

Stock chart